产品说明书
Eicosapentaenoic Acid
 |
同义名 : | 二十碳五烯酸 ;EPA;Timnodonic acid;Icosapent, Eicosapentaenoic acid, Timnodonic acid, Vascepa, Epadel, EPAX;omega-3 Fatty acid;5-LOX inhibitor];C20:5 (all cis-5,8,11,14,17) Fatty acid [Anti-hyperlipoproteinenic agent;Eicosapentaenoic acid (all cis-5,8,11,14,17) |
| CAS号 : | 10417-94-4 | |
| 货号 : | A216225 | |
| 分子式 : | C20H30O2 | |
| 纯度 : | 95% | |
| 分子量 : | 302.451 | |
| MDL号 : | MFCD00065716 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 30 mg/mL(99.19 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 100 mg/mL(330.63 mM)，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, lowers plasma triglyceride levels without raising low-density lipoprotein cholesterol levels and has potential beneficial effects on atherosclerotic plaques. EPA reduces levels of pro-inflammatory cytokines and chemokines[3]. EPA (Eicosapentaenoic Acid) may be more efficacious than DHA (docosahexaenoic acid) in treating depression[4]. The addition of eicosapentaenoic acid (EPA) to statins further reduced cardiovascular events in clinical trials, JELIS and REDUCE-IT. EPA significantly suppressed arterial calcification in vitro and in vivo via suppression of inflammatory responses, oxidative stress and Wnt signaling[5]. The effects of EPA in reducing the risk of CVD (cardiovascular disease) could be mediated by biological action of PGI3 in addition to hypotriglyceridemic action of EPA. Compared with DHA, EPA administration increases the EPA/AA ratio and the (PGI2 + PGI3)/TXA2 (thromboxane A2)balance to a state that inhibits the onset and/or progression of CVD[6]. EPA had the most favorable molecular structure, likely contributing to membrane stability, improved lipoprotein clearance, and reduced inflammation[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01002118 | Cardiovascular Disease | Not Applicable | Terminated(Unable to recruit e... 展开 >>ligible subjects; no data analyzed) 收起 << | - | United States, Iowa ... 展开 >> University of Iowa Iowa City, Iowa, United States, 52242 收起 << |
| NCT03192579 | Coronary Artery Disease Progre... 展开 >>ssion 收起 << | Phase 4 | Completed | - | - |
| NCT00350194 | Metabolic Syndrome X | Early Phase 1 | Unknown | June 2012 | United States, Washington ... 展开 >> Northwest Lipid Research Clinic (University of Washington Affiliated) Seattle, Washington, United States, 98104 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.31mL 0.66mL 0.33mL |
16.53mL 3.31mL 1.65mL |
33.06mL 6.61mL 3.31mL |
| 参考文献 |
|---|